Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Hinova Pharmaceuticals Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These filings are distributed across 2 distinct art units, indicating that the company's research involves multiple specialized examination groups. The involvement of distinct examiners suggests that the prosecution is not concentrated under a single individual, allowing for a more diversified review of the portfolio.
FOWLER, ALAN JEROME is the busiest examiner for the company, currently overseeing 1 pending office action. This specific action represents half of the pending office actions currently active for the portfolio. Practitioners should monitor the progress of FOWLER, ALAN JEROME to gauge potential timelines and procedural expectations for the biotechnology filings. Because the distinct examiners are operating in separate art units, the company must tailor its responses to the specific standards of each technical division.
The alignment of the distinct examiners with the distinct art units suggests a one-to-one ratio in this dataset, which may simplify the coordination of technical arguments. However, the presence of 1 pending office action with the busiest examiner means that any delays in that specific case will impact a significant portion of the active workload. Practitioners should prioritize a thorough response to the pending office actions to maintain momentum across the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FOWLER, ALAN JEROME | 1 | 100.0% | +0.0% |
| ABBAS, ABDULRAHMAN MUSTAFA | 1 | 52.4% | +34.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293289 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | FOWLER, ALAN JEROME | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17055862 | HC-1119 FORMULATION, PREPARATION METHOD AND USE THEREOF | ABBAS, ABDULRAHMAN MUSTAFA | 70d |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18293289 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | FOWLER, ALAN JEROME | 1691 | §102§103§112 | Non-Final OA | — | Pending | Jan 29, 2024 |
| 17055862 | HC-1119 FORMULATION, PREPARATION METHOD AND USE THEREOF | ABBAS, ABDULRAHMAN MUSTAFA | 1612 | §103 | Final Rejection | 70d | Pending | Jun 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial